医药政策法规
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-15)
- (2021-10-14)
- (2021-10-14)
- (2021-10-14)
- (2021-10-14)
- (2021-10-14)
- (2021-10-14)
食管鳞状细胞癌(ESCC)免疫医治!2种Opdivo方案(+化疗、+Yervoy)在美欧进入审查:显著缩短总生活期(OS)!
(2021-10-13)- (2021-10-13)
- (2021-10-13)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-12)
- (2021-10-11)
- (2021-10-11)
- (2021-10-11)
- (2021-10-11)
- (2021-10-11)
- (2021-10-11)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-09)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
Bioresources and Bioprocessing:提醒酿酒酵母类胡萝卜素合成中的顺应性退化战略和最新代谢工程改革靶点
(2021-10-08)- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-10-08)
- (2021-09-29)
J IMMUNOTHER CANCER:CTLA4启动子低甲基化在初始诊断时是一种阴性预后生物标记物,但可预测通明细胞肾细胞癌中基于抗PD
(2021-09-29)- (2021-09-29)
- (2021-09-29)
- (2021-09-29)
- (2021-09-29)
- (2021-09-29)
- (2021-09-28)